Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Combination Trial to Evaluate Safety, Tolerability and Pharmacokinetics of FPI-1434 in Combination with Pembrolizumab in Patients With Solid Tumors Expressing IGF-1R

X
Trial Profile

A Phase 1/2 Combination Trial to Evaluate Safety, Tolerability and Pharmacokinetics of FPI-1434 in Combination with Pembrolizumab in Patients With Solid Tumors Expressing IGF-1R

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 21 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 225 Actinium FPI 1434 (Primary) ; Pembrolizumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Fusion Pharmaceuticals
  • Most Recent Events

    • 16 Mar 2023 According to Fusion media release, company anticipates the initiation of this study to occur 6 to 9 months following determination of the recommended phase II dose of FPI-1434 monotherapy.
    • 09 Nov 2021 According to a Fusion Pharmaceuticals media release, anticipate the initiation of a Phase 1 combination study with FPI-1434 and KEYTRUDA (pembrolizumab) to occur six to nine months following determination of the recommended Phase 2 dose of FPI 1434 monotherapy.The shift in timelines is primarily associated with a decrease in patient enrollment rates attributable to the impact of the COVID-19 pandemic.
    • 06 May 2021 According to a Fusion Pharmaceuticals media release, the company has entered into a clinical trial collaboration with a subsidiary of Merck (known as MSD outside the U.S. and Canada) to evaluate [225Ac]-FPI-1434 (FPI-1434) in combination with KEYTRUDA (pembrolizumab), in patients with solid tumors expressing insulin-like growth factor 1 receptor (IGF-1R).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top